121 related articles for article (PubMed ID: 38527289)
21. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
22. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
[TBL] [Abstract][Full Text] [Related]
23. The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022).
Willem L; Abrams S; Franco N; Coletti P; Libin PJK; Wambua J; Couvreur S; André E; Wenseleers T; Mao Z; Torneri A; Faes C; Beutels P; Hens N
BMC Public Health; 2024 Apr; 24(1):1171. PubMed ID: 38671366
[TBL] [Abstract][Full Text] [Related]
24. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
Callegaro A; Borleri D; Farina C; Napolitano G; Valenti D; Rizzi M; Maggiolo F
J Med Virol; 2021 Jul; 93(7):4612-4615. PubMed ID: 33788281
[TBL] [Abstract][Full Text] [Related]
25. Direct impact of COVID-19 vaccination in Chile: averted cases, hospitalizations, ICU admissions, and deaths.
Brault A; Hart A; Uribe P; Prado J; San Martín J; Maass A; Canals M
BMC Infect Dis; 2024 May; 24(1):467. PubMed ID: 38698324
[TBL] [Abstract][Full Text] [Related]
26. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study.
Moore S; Hill EM; Tildesley MJ; Dyson L; Keeling MJ
Lancet Infect Dis; 2021 Jun; 21(6):793-802. PubMed ID: 33743847
[TBL] [Abstract][Full Text] [Related]
27. Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
Lin DY; Xu Y; Gu Y; Zeng D; Wheeler B; Young H; Moore Z; Sunny SK
Lancet Infect Dis; 2023 Nov; 23(11):1257-1265. PubMed ID: 37336222
[TBL] [Abstract][Full Text] [Related]
28. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.
Taylor CA; Whitaker M; Anglin O; Milucky J; Patel K; Pham H; Chai SJ; Alden NB; Yousey-Hindes K; Anderson EJ; Teno K; Reeg L; Como-Sabetti K; Bleecker M; Barney G; Bennett NM; Billing LM; Sutton M; Talbot HK; McCaffrey K; Havers FP;
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(12):466-473. PubMed ID: 35324880
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
Natarajan K; Prasad N; Dascomb K; Irving SA; Yang DH; Gaglani M; Klein NP; DeSilva MB; Ong TC; Grannis SJ; Stenehjem E; Link-Gelles R; Rowley EA; Naleway AL; Han J; Raiyani C; Benitez GV; Rao S; Lewis N; Fadel WF; Grisel N; Griggs EP; Dunne MM; Stockwell MS; Mamawala M; McEvoy C; Barron MA; Goddard K; Valvi NR; Arndorfer J; Patel P; Mitchell PK; Smith M; Kharbanda AB; Fireman B; Embi PJ; Dickerson M; Davis JM; Zerbo O; Dalton AF; Wondimu MH; Azziz-Baumgartner E; Bozio CH; Reynolds S; Ferdinands J; Williams J; Schrag SJ; Verani JR; Ball S; Thompson MG; Dixon BE
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(13):495-502. PubMed ID: 35358170
[TBL] [Abstract][Full Text] [Related]
30. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
[TBL] [Abstract][Full Text] [Related]
31. How the Timing of Annual COVID-19 Vaccination of Nursing Home Residents and Staff Affects Its Value.
Bartsch SM; Weatherwax C; Wasserman MR; Chin KL; Martinez MF; Velmurugan K; Singh RD; John DC; Heneghan JL; Gussin GM; Scannell SA; Tsintsifas AC; O'Shea KJ; Dibbs AM; Leff B; Huang SS; Lee BY
J Am Med Dir Assoc; 2024 Apr; 25(4):639-646.e5. PubMed ID: 38432644
[TBL] [Abstract][Full Text] [Related]
32. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
[TBL] [Abstract][Full Text] [Related]
33. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
35. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
Thompson MG; Stenehjem E; Grannis S; Ball SW; Naleway AL; Ong TC; DeSilva MB; Natarajan K; Bozio CH; Lewis N; Dascomb K; Dixon BE; Birch RJ; Irving SA; Rao S; Kharbanda E; Han J; Reynolds S; Goddard K; Grisel N; Fadel WF; Levy ME; Ferdinands J; Fireman B; Arndorfer J; Valvi NR; Rowley EA; Patel P; Zerbo O; Griggs EP; Porter RM; Demarco M; Blanton L; Steffens A; Zhuang Y; Olson N; Barron M; Shifflett P; Schrag SJ; Verani JR; Fry A; Gaglani M; Azziz-Baumgartner E; Klein NP
N Engl J Med; 2021 Oct; 385(15):1355-1371. PubMed ID: 34496194
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
38. Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.
Jung SM; Loo SL; Howerton E; Contamin L; Smith CP; Carcelén EC; Yan K; Bents SJ; Levander J; Espino J; Lemaitre JC; Sato K; McKee CD; Hill AL; Chinazzi M; Davis JT; Mu K; Vespignani A; Rosenstrom ET; Rodriguez-Cartes SA; Ivy JS; Mayorga ME; Swann JL; España G; Cavany S; Moore SM; Perkins TA; Chen S; Paul R; Janies D; Thill JC; Srivastava A; Aawar MA; Bi K; Bandekar SR; Bouchnita A; Fox SJ; Meyers LA; Porebski P; Venkatramanan S; Adiga A; Hurt B; Klahn B; Outten J; Chen J; Mortveit H; Wilson A; Hoops S; Bhattacharya P; Machi D; Vullikanti A; Lewis B; Marathe M; Hochheiser H; Runge MC; Shea K; Truelove S; Viboud C; Lessler J
PLoS Med; 2024 Apr; 21(4):e1004387. PubMed ID: 38630802
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
Klein NP; Stockwell MS; Demarco M; Gaglani M; Kharbanda AB; Irving SA; Rao S; Grannis SJ; Dascomb K; Murthy K; Rowley EA; Dalton AF; DeSilva MB; Dixon BE; Natarajan K; Stenehjem E; Naleway AL; Lewis N; Ong TC; Patel P; Konatham D; Embi PJ; Reese SE; Han J; Grisel N; Goddard K; Barron MA; Dickerson M; Liao IC; Fadel WF; Yang DH; Arndorfer J; Fireman B; Griggs EP; Valvi NR; Hallowell C; Zerbo O; Reynolds S; Ferdinands J; Wondimu MH; Williams J; Bozio CH; Link-Gelles R; Azziz-Baumgartner E; Schrag SJ; Thompson MG; Verani JR
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):352-358. PubMed ID: 35239634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
